Drugs / ASP1951
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03799003 | Jan 2019 → Jul 2023 | cancer | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03799003 ↗ |
| Known as | PTZ-522 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650445 ↗ |
| Action | Activate | “ASP1951, a GITR Agonistic Antibody” NCT03799003 ↗ |